Literature DB >> 23113638

The DC-HIL ligand syndecan-4 is a negative regulator of T-cell allo-reactivity responsible for graft-versus-host disease.

Jin-Sung Chung1, Mizuki Tomihari, Kyoichi Tamura, Tetsuhito Kojima, Ponciano D Cruz, Kiyoshi Ariizumi.   

Abstract

Acute graft-versus-host disease (GVHD) is the most important cause of mortality after allogeneic haematopoietic stem cell transplantation. Allo-reactive T cells are the major mediators of GVHD and the process is regulated by positive and negative regulators on antigen-presenting cells (APC). Because the significance of negative regulators in GVHD pathogenesis is not fully understood, and having discovered that syndecan-4 (SD-4) on effector T cells mediates the inhibitory function of DC-HIL on APC, we proposed that SD-4 negatively regulates the T-cell response to allo-stimulation in acute GVHD, using SD-4 knockout mice. Although not different from their wild-type counterparts in responsiveness to anti-CD3 stimulation, SD-4(-/-) T cells lost the capacity to mediate the inhibitory function of DC-HIL and were hyper-reactive to allogeneic APC. Moreover, infusion of SD-4(-/-) T cells into sub-lethally γ-irradiated allogeneic mice worsened mortality, with hyper-proliferation of infused T cells in recipients. Although there my be little or no involvement of regulatory T cells in this model because SD-4 deletion had no deleterious effect on T-cell-suppressive activity compared with SD-4(+/+) regulatory T cells. We conclude that SD-4, as the T-cell ligand of DC-HIL, is a potent inhibitor of allo-reactive T cells responsible for GVHD and a potentially useful target for treating this disease. Published 2012. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23113638      PMCID: PMC3575770          DOI: 10.1111/imm.12027

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  40 in total

1.  DC-HIL is a negative regulator of T lymphocyte activation.

Authors:  Jin-Sung Chung; Kota Sato; Irene I Dougherty; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

2.  Syndecan-4 deficiency impairs focal adhesion formation only under restricted conditions.

Authors:  K Ishiguro; K Kadomatsu; T Kojima; H Muramatsu; S Tsuzuki; E Nakamura; K Kusugami; H Saito; T Muramatsu
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

3.  Cytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T-cell-mediated suppression.

Authors:  Cecilia Oderup; Lukas Cederbom; Anna Makowska; Corrado M Cilio; Fredrik Ivars
Journal:  Immunology       Date:  2006-06       Impact factor: 7.397

4.  Inhibition of T-cell activation by syndecan-4 is mediated by CD148 through protein tyrosine phosphatase activity.

Authors:  Jin-Sung Chung; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Eur J Immunol       Date:  2011-05-09       Impact factor: 5.532

Review 5.  The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection.

Authors:  Arlene H Sharpe; E John Wherry; Rafi Ahmed; Gordon J Freeman
Journal:  Nat Immunol       Date:  2007-03       Impact factor: 25.606

6.  Syndecan-4 deficiency leads to high mortality of lipopolysaccharide-injected mice.

Authors:  K Ishiguro; K Kadomatsu; T Kojima; H Muramatsu; M Iwase; Y Yoshikai; M Yanada; K Yamamoto; T Matsushita; M Nishimura; K Kusugami; H Saito; T Muramatsu
Journal:  J Biol Chem       Date:  2001-10-03       Impact factor: 5.157

7.  CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers.

Authors:  P M Wallace; J S Johnson; J F MacMaster; K A Kennedy; P Gladstone; P S Linsley
Journal:  Transplantation       Date:  1994-09-15       Impact factor: 4.939

8.  Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4.

Authors:  F Echtermeyer; M Streit; S Wilcox-Adelman; S Saoncella; F Denhez; M Detmar; P Goetinck
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

9.  Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism.

Authors:  Bruce R Blazar; Beatriz M Carreno; Angela Panoskaltsis-Mortari; Laura Carter; Yoshiko Iwai; Hideo Yagita; Hiroyuki Nishimura; Patricia A Taylor
Journal:  J Immunol       Date:  2003-08-01       Impact factor: 5.422

10.  Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation.

Authors:  Jin-Sung Chung; Irene Dougherty; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  J Immunol       Date:  2007-11-01       Impact factor: 5.422

View more
  13 in total

1.  Generation and functional characterization of MDSC-like cells.

Authors:  Annkristin Heine; Stefanie Andrea Erika Held; Jonas Schulte-Schrepping; Julia Friederike Andrea Wolff; Kathrin Klee; Thomas Ulas; Niklas Arndt Schmacke; Solveig Nora Daecke; Kati Riethausen; Joachim L Schultze; Peter Brossart
Journal:  Oncoimmunology       Date:  2017-02-23       Impact factor: 8.110

Review 2.  Glycoprotein nonmetastatic melanoma protein B: A key mediator and an emerging therapeutic target in autoimmune diseases.

Authors:  Pei-Suen Tsou; Amr H Sawalha
Journal:  FASEB J       Date:  2020-05-23       Impact factor: 5.191

3.  Myeloid-Derived Suppressor Cells in Psoriasis Are an Expanded Population Exhibiting Diverse T-Cell-Suppressor Mechanisms.

Authors:  Lauren Y Cao; Jin-Sung Chung; Takahiro Teshima; Lawrence Feigenbaum; Ponciano D Cruz; Heidi T Jacobe; Benjamin F Chong; Kiyoshi Ariizumi
Journal:  J Invest Dermatol       Date:  2016-05-25       Impact factor: 8.551

Review 4.  GPNMB: a potent inducer of immunosuppression in cancer.

Authors:  Anna-Maria Lazaratos; Matthew G Annis; Peter M Siegel
Journal:  Oncogene       Date:  2022-09-01       Impact factor: 8.756

5.  The DC-HIL/syndecan-4 pathway regulates autoimmune responses through myeloid-derived suppressor cells.

Authors:  Jin-Sung Chung; Kyoichi Tamura; Hideo Akiyoshi; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  J Immunol       Date:  2014-02-10       Impact factor: 5.422

Review 6.  Syndecan-4 signaling at a glance.

Authors:  Arye Elfenbein; Michael Simons
Journal:  J Cell Sci       Date:  2013-08-22       Impact factor: 5.285

7.  The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells.

Authors:  Michael Gutknecht; Julian Geiger; Simone Joas; Daniela Dörfel; Helmut R Salih; Martin R Müller; Frank Grünebach; Susanne M Rittig
Journal:  Cell Commun Signal       Date:  2015-03-24       Impact factor: 5.712

8.  Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer.

Authors:  Gordana Maric; April An Rose; Matthew G Annis; Peter M Siegel
Journal:  Onco Targets Ther       Date:  2013-07-09       Impact factor: 4.147

9.  DC-HIL+ CD14+ HLA-DR no/low cells are a potential blood marker and therapeutic target for melanoma.

Authors:  Jake Turrentine; Jin-Sung Chung; Kaveh Nezafati; Kyoichi Tamura; Amy Harker-Murray; James Huth; Rohit R Sharma; David B Harker; Kiyoshi Ariizumi; Ponciano D Cruz
Journal:  J Invest Dermatol       Date:  2014-06-16       Impact factor: 8.551

10.  Beneficial impact of Gpnmb and its significance as a biomarker in nonalcoholic steatohepatitis.

Authors:  Akihiro Katayama; Atsuko Nakatsuka; Jun Eguchi; Kazutoshi Murakami; Sanae Teshigawara; Motoko Kanzaki; Tomokazu Nunoue; Kazuyuki Hida; Nozomu Wada; Tetsuya Yasunaka; Fusao Ikeda; Akinobu Takaki; Kazuhide Yamamoto; Hiroshi Kiyonari; Hirofumi Makino; Jun Wada
Journal:  Sci Rep       Date:  2015-11-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.